Published by Iain Gilbert on 4th October 2017
(ShareCast News) - US-based generic and speciality pharmaceuticals company Mylan announced on Tuesday that the US Food and Drug Administration (FDA) had approved two doses of its generic equivalent to Teva's drug Copaxone, which generated $1.02bn worth of sales in the second quarter of 2017, used to treat relapsing forms of multiple sclerosis.